Shots:
- Intas has acquired Coherus’ Udenyca business (incl. prefilled syringe, autoinjector & on-body injector), a biosimilar version of Amgen’s Neulasta (pegfilgrastim) via 2024 asset purchase agreement; Accord BioPharma (Intas’ US specialty division) will handle Udenyca’s US business
- As per the deal, Coherus received $483.4M upfront in cash, incl. $118.4M for Udenyca inventory, with an additional ~$75M contingent on Intas achieving 2 predefined sales-based milestones
- Coherus will get $250M post-close cash balance, extending its cash runway into 2027 to support pipeline development, incl. loqtorzi (PD-1 inhibitor), casdozokitug (IL-27 antagonist), & CHS-114 (selective CCR8 antibody)
Ref: Coherus | Image: Intas & Coherus
Related News:- Bio-Thera Collaborates with Intas Pharmaceuticals for the Commercialization of BAT2506 (Biosimilar, Simponi) Across the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
